Tele: 561.316.3330
Breaking Medical Device News

Monday, October 18, 2021
HomeFDAETS Wound Care Gains FDA Clearance for MIRRAGEN ™ Advanced Wound Matrix

ETS Wound Care Gains FDA Clearance for MIRRAGEN ™ Advanced Wound Matrix

MARKET REPORTS

Global $45 Billion Endoscopy Market Insights & Forecasts to 2025

The global endoscopy market is predicted to reach US$45.28 billion in 2025, growing, at a CAGR of 7.50%, for the duration spanning 2021-2025.

Global Remote Monitoring Devices Market Research Report (2021 to 2026)

Global Remote Monitoring Devices Market size was estimated at USD 1,035.35 million in 2020, is expected to reach USD 1,170.22 million in 2021.

Research Efforts Fuel the Future of Global Obstructive Lung Disease Management Markets – ResearchAndMarkets.com

The "Global Obstructive Lung Disease Management Research Report" report has been added.

Global Electrophysiology Market (2021 to 2026) – Growth, Trends , COVID-19 Impact and Forecasts – ResearchAndMarkets.com

The Electrophysiology Market is expected to register a CAGR of 8.5% during the forecast period.

ETS Wound Care LLC, an Engineered Tissue Solutions (ETS) subsidiary focused on commercializing next generation wound care solutions, announced MIRRAGEN™ Advanced Wound Matrix, MIRRAGEN was cleared by the United States Food and Drug Administration (FDA) for treatment of acute and chronic wounds.

ETS Wound Care notes MIRRAGEN is a fully resorbable borate glass matrix comprised of fibers and beads proven to be highly effective in wound care management.

MIRRAGEN™ represents a breakthrough discovery for chronic and acute wound management due to its unique borate-based fiber matrix. MIRRAGEN™ is packed into wounds to manage and control wound fluids, while the resorbable matrix provides an environment for optimal wound healing.

“Anyone who is treating or experiencing discomfort from acute or chronic wounds will immediately recognize the benefits of MIRRAGEN™,” said Peggy Earl, BSN, RN, WOCN, a wound care specialist at Phelps County Regional Medical Center located in Rolla, Missouri. “MIRRAGEN™ has the potential to reduce the required number of episodes and duration of wound care treatment, while allowing the body to effectively heal a variety of wounds, both acute and chronic.”

“The recent FDA approval is a significant milestone for ETS,” said Chad Lewis, PhD, ETS Wound Care President & CEO. “ETS Wound Care is pioneering an entirely new therapeutic option for wound care. The MIRRAGEN™ Advanced Wound Matrix is the first product utilizing our innovative borate fiber technology engineered to improve patient outcomes.”

ETS Wound Care plans to make MIRRAGEN™ commercially available via a controlled domestic market release in early Q2 2017 and available to the broader domestic market in 2018. Later this week, the Company will be an exhibitor at the Nation’s largest interdisciplinary wound care forum – the Symposium on Advanced Wound Care Spring meeting (SAWC Spring) from April 6-8, 2017 in San Diego.

spot_img

DON'T MISS

AMRA Medical’s Whole-body MRI Analysis Used in FSHD Clinical Trial Research Network Study for Biomarker Development

To date, the MOVE study has used functional tests as primary outcomes, but recent studies have shown the promise of MRI for FSHD.

Aethlon Medical Announces Peer-Reviewed Publication of Two Case Studies of Critically Ill COVID-19 Patients Treated with the Hemopurifier®

The publication documents two critically ill COVID-19 patients receiving a combined total of nine, six-hour Hemopurifier® treatment sessions.

Koya Medical Presents Positive Interim Data from Randomized Trial Comparing its Dayspring Lymphedema Treatment to Pneumatic Compression

For people with lymphedema, movement is important from both a clinical perspective and a quality-of-life perspective. These data illustrate the Dayspring treatment’s ability to provide that essential movement while still delivering the clinical outcomes we need from compression therapy.

18-Month Below-the-Knee Data with MedAlliance’s SELUTION SLR™ Presented as Late Breaking Trial at VIVA

“We have observed minimal slow-flow phenomena, seen with other paclitaxel drug-eluting balloons.  We have observed several cases of fast wound healing with SELUTION SLR. It is easy to track and deliver. We are looking forward to gaining further clinical experience with this device,” commented Prof. Chong.

Our Sister Publication: Biotechnology News Magazine

By using this website you agree to accept Medical Device News Magazine Privacy Policy